Zai Lab Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZLAB Nasdaq 2836 www.zailaboratory.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zai Lab Limited

Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - Jan 15th, 2026 8:37 am
Is Zai Lab (ZLAB) Pricing Reflect Its Potential After Multi‑Year Share Price Slump - Jan 14th, 2026 12:11 pm
Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading - Jan 14th, 2026 8:36 am
Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading - Jan 13th, 2026 8:48 am
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Jan 13th, 2026 6:00 am
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading - Jan 12th, 2026 8:42 am
UBS Gives Zai Lab (ZLAB) a Buy Rating - Jan 9th, 2026 1:16 am
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After AUGTYRO’s First NTRK Fusion Approval In China - Jan 8th, 2026 5:13 am
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - Jan 7th, 2026 8:43 am
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - Jan 6th, 2026 5:30 am
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - Jan 5th, 2026 8:47 am
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:30 am
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; 2% for Week - Dec 26th, 2025 8:47 am
Asian Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading - Dec 24th, 2025 8:43 am
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Dec 23rd, 2025 5:30 am
Does Zai Lab’s Steep 86.2% Slide Mask a Long Term Value Opportunity? - Dec 15th, 2025 1:10 pm
Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat - Dec 12th, 2025 8:44 am
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Dec 8th, 2025 5:00 am
Zai Lab Announces Updates to China’s National Reimbursement Drug List - Dec 6th, 2025 10:11 pm
Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum - Nov 30th, 2025 3:41 am